ReviewBiotechnology and bioengineering2016
Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.
Review in Biotechnology and bioengineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering.Diabetes/metabolism research and reviews · 2026Review
- Stem cell-based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection.Animal models and experimental medicine · 2026Review
- Hydrogel injection molded complex macroencapsulation device geometry improves long-term cell therapy viability and function in the rat omentum transplant site.Biomaterials · 2025Article
- Supporting islet function in a PVDF membrane based macroencapsulation delivery device by solvent non-solvent casting using PVP.PloS one · 2025Article
- pOJournal of biomedical materials research. Part A · 2024Article
- Immunoprotection Strategies in β-Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Voxelated bioprinting of modular double-network bio-ink droplets.Nature communications · 2024Article
- Advances and challenges of the cell-based therapies among diabetic patients.Journal of translational medicine · 2024Review
- Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts.Nature biomedical engineering · 2024Article
- Research progress of autoimmune diseases based on induced pluripotent stem cells.Frontiers in immunology · 2024Review
- Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.iScience · 2023Article
- Characterization of human islet function in a convection-driven intravascular bioartificial pancreas.Bioengineering & translational medicine · 2023Article
- Association of MicroRNA-146a with Type 1 and 2 Diabetes and their Related Complications.Journal of diabetes research · 2023Review
- Type 1 diabetes and engineering enhanced islet transplantation.Advanced drug delivery reviews · 2022Review
- A novel in vitro approach to test the effectiveness of fish oil in ameliorating type 1 diabetes.Molecular and cellular biochemistry · 2022Article
- Performance of islets of Langerhans conformally coated via an emulsion cross-linking method in diabetic rodents and nonhuman primates.Science advances · 2022Article
- Integrating Additive Manufacturing Techniques to Improve Cell-Based Implants for the Treatment of Type 1 Diabetes.Advanced healthcare materials · 2022Review
- Molecularly Tailored Interface for Long-Term Xenogeneic Cell Transplantation.Advanced functional materials · 2022Article
- Oral Administration of BacterialOxidative medicine and cellular longevity · 2022Article
- PEGDA microencapsulated allogeneic islets reverse canine diabetes without immunosuppression.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Macroencapsulation technology has been an attractive topic in the field of treatment for Type 1 diabetes due to mechanical stability, versatility, and retrievability of the macro-capsule design. Macro-capsules can be categorized into extravascular and intravascular devices, in which solute transport relies either on diffusion or convection, respectively. Failure of macroencapsulation strategies can be due to limited regenerative capacity of the encased insulin-producing cells, sub-optimal performance of encapsulation biomaterials, insufficient immunoisolation, excessive blood thrombosis for vascular perfusion devices, and inadequate modes of mass transfer to support cell viability and function. However, significant technical advancements have been achieved in macroencapsulation technology, namely reducing diffusion distance for oxygen and nutrients, using pro-angiogenic factors to increase vascularization for islet engraftment, and optimizing membrane permeability and selectivity to prevent immune attacks from host's body. This review presents an overview of existing macroencapsulation devices and discusses the advances based on tissue-engineering approaches that will stimulate future research and development of macroencapsulation technology. Biotechnol. Bioeng. 2016;113: 1381-1402. © 2015 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.